Global Cancer Biological Therapy Market By Product Type (Vaccines, Monoclonal Antibodies, and Cancer Growth Blockers), By Route of Administration (Oral and Injectable), By End-User (Hospitals & Clinics, Cancer Research Centres, and Laboratories), By Distribution Channel (Specialized Cancer Treatment Centers, Hospital Pharmacies, and Retail Pharmacies), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032
- Published date: Oct 2023
- Report ID: 66398
- Number of Pages: 346
- Format:
-
-
-
- Merck & Co., Inc.
- Hoffmann-La Roche Ltd
- Novartis AG Company Profile
- Amgen Inc.
- Bristol-Myers Squibb Company
- Celgene
- Eli Lilly and Company (US)
- EnGeneIC
- Pfizer Inc Company Profile
- Intas Pharmaceuticals Ltd.
- Astellas Pharma, Inc Company Profile
- Otsuka
- Teva Pharmaceutical Industries Ltd. Company Profile
- Bayer AG Company Profile
- GlaxoSmithKline PLC
- AbbVie Inc. Company Profile
- Astellas Pharma Inc.
- Seattle Genetics
- Takeda Pharmaceuticals
- Spectrum Pharmaceuticals
- Bausch Health Companies Inc.
- Johnson & Johnson Services, Inc.
- AstraZeneca Plc Company Profile
- Other Key Players
- settingsSettings
Our Clients
✖
Request a Sample Report
We'll get back to you as quickly as possible
Single User
$6,000
$3,999
USD / per unit
save 24%
|
Multi User
$8,000
$5,999
USD / per unit
save 28%
|
Corporate User
$10,000
$6,999
USD / per unit
save 32%
|
|
---|---|---|---|
e-Access | |||
Report Library Access | |||
Data Set (Excel) | |||
Company Profile Library Access | |||
Interactive Dashboard | |||
Free Custumization | No | up to 10 hrs work | up to 30 hrs work |
Accessibility | 1 User | 2-5 User | Unlimited |
Analyst Support | up to 20 hrs | up to 40 hrs | up to 50 hrs |
Benefit | Up to 20% off on next purchase | Up to 25% off on next purchase | Up to 30% off on next purchase |
Buy Now ($ 3,999) | Buy Now ($ 5,999) | Buy Now ($ 6,999) |